One study found that sodium glucose co-transport 2 (SGLT2) inhibitor restored insulin content and β-cell function by reducing oxidative and ER stress of β-cells in monogenic neonatal diabetes mellitus with insulin secretory-deficient[44], which showed that SGLT was involved in the control of β-cell function. The gene discussed is SLC5A2; the disease is neonatal diabetes mellitus.